Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

244279

Sigma-Aldrich

Hydrofluoric acid

ACS reagent, 48%

Synonym(s):

HF

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
HF
CAS Number:
7664-39-3
Molecular Weight:
20.01
MDL number:
MFCD00011346
UNSPSC Code:
12352106
PubChem Substance ID:
24854662

grade

ACS reagent

vapor density

1.27 (vs air)

vapor pressure

25 mmHg ( 20 °C)

Assay

48%
48.0-51.0% (ACS specification)

form

liquid

impurities

≤0.01% fluorosilicic acid

ign. residue

≤5 ppm

density

1.15 g/mL at 25 °C (lit.)

anion traces

SO42- and SO32-: ≤5 ppm
chloride (Cl-): ≤5 ppm
phosphate (PO43-): ≤1 ppm

cation traces

As: ≤0.005 ppm
Cu: ≤0.1 ppm
Fe: ≤1 ppm
heavy metals (as Pb): ≤0.5 ppm

SMILES string

[H+].[F-]

InChI

1S/FH/h1H

InChI key

KRHYYFGTRYWZRS-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Other Notes

This product has been replaced by 695068-Sigma-Aldrich | Hydrofluoric acid, ACS reagent, 48% | HF

Pictograms

Skull and crossbonesCorrosion
GHS06,GHS05

Signal Word

Danger

Hazard Statements

H300 + H310 + H330,H314

Hazard Classifications

Acute Tox. 1 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - Eye Dam. 1 - Skin Corr. 1A

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
89997PJ
08385TH
03555EH
05657AH
03392PV

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ian Ford et al.
International journal of cardiology, 184, 163-169 (2015-02-24)
We identified easily obtained baseline characteristics associated with outcomes in patients with chronic heart failure (HF) and elevated heart rate (HR) receiving contemporary guideline-recommended therapy in the SHIFT trial, and used them to develop a prognostic model. We selected the
Wenlin Yvonne Lin et al.
Waste management (New York, N.Y.), 41, 75-84 (2015-04-22)
Accelerated carbonation has been studied as a treatment method for MSW IBA, and the main advantage is that it can shorten the treatment duration from months to days, compared to natural weathering. This study investigated the effect of accelerated carbonation
Yvonne C J Wientjes et al.
Genetics, selection, evolution : GSE, 47, 42-42 (2015-05-09)
Although simulation studies show that combining multiple breeds in one reference population increases accuracy of genomic prediction, this is not always confirmed in empirical studies. This discrepancy might be due to the assumptions on quantitative trait loci (QTL) properties applied
Faiez Zannad et al.
European journal of heart failure, 17(7), 735-742 (2015-04-29)
Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after
Barry Greenberg et al.
JACC. Heart failure, 2(1), 84-92 (2014-03-14)
Impaired cardiac isoform of sarco(endo)plasmic reticulum Ca(2+) ATPase (SERCA2a) activity is a key abnormality in heart failure patients with reduced ejection fraction. The CUPID 2 (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b) trial is
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service